<DOC>
	<DOCNO>NCT01650506</DOCNO>
	<brief_summary>Extended phase 1 trial combine metformin erlotinib advance triple negative breast cancer patient .</brief_summary>
	<brief_title>Study Erlotinib Metformin Triple Negative Breast Cancer</brief_title>
	<detailed_description>The goal study establish maximum tolerated combine dose erlotinib metformin well decide potential clinical utility combination treat patient triple negative breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Confirmed pathologic diagnosis triple negative breast cancer , OR Prior diagnosis ER PR positive breast cancer [ HER2 negative ] demonstrate ER PR negative ( rare stain ) patient 's recent biopsy . Patients measurable nonmeasurable metastatic disease ( RECIST 1.1 ) . At least one prior treatment metastatic disease . Availability adequate tumor tissue exploratory analysis plan obtain material ( see section 12.6 ) . Patients must recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . No chemotherapy radiotherapy may give within 2 week prior start protocol treatment . Patients must ≥ 18 &lt; 80 year old . Performance Status : ECOG 02 . Life expectancy great 12 week . Patients must recover uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris cardiac arrhythmia . Required Laboratory Values : ANC ≥1,250/mm3 , platelet ≥75,000/mm3 , hemoglobin ≥8.5 g/dL , total bilirubin ≤1.5 x ULN , AST/ALT ≤3.0 x ULN , alkaline phosphatase ≤2.5 x ULN , Patients must either normal serum creatinine ( &lt; = IULN ) OR estimate creatinine clearance ≥ 60 ml/min ( CockcroftGault formula ) within 14 day prior registration . Concomitant Medications : Erlotinib primarily metabolize CYP3A4 . Patients CAN NOT receive enzymeinducing enzyme inhibit agent list : Inhibitors : Amiodarone , Amprenavir , Atazanavir , Chloramphenicol , Clarithromycin , Conivaptan , Cyclosporine , Darunavir , Dasatinib , Delavirdine , Diltiazem , Erythromycin , Fluconazole , Fluoxetine , Fluvoxamine , Fosamprenavir , Imatinib , Indinavir , Isoniazid , Itraconazole , Ketoconazole , Lapatinib , Miconazole , Nefazodone , Nelfinavir , Posaconazole , Ritonavir , Quinupristin , Saquinavir , Tamoxifen , Telithromycin , Troleandomycin , Verapamil , Voriconazole . Inducers : Aminoglutethimide , Bexarotene , Bosentan , Carbamazepine , Efavirenz , Fosphenytoin , Griseofulvin , Modafinil , Nafcillin , Nevirapine , Oxcarbazepine , Phenobarbital , Phenytoin , Primidone , Rifabutin , Rifampin , Rifapentine , St. John 's wort , Sulfadimidine , Sulfinpyrazone , Troglitazone , Troleandomycin . All concomitant medication must record . Sexually Active Patients : For sexually active patient , use adequate contraception ( hormonal barrier method birth control ) require prior study entry duration study participation . Nonpregnant status determine woman childbearing potential . Patients must sign approve informed consent . Active CNS disease . Subjects history CNS metastases cord compression allowable clinically stable least 6 week since completion definitive treatment , steroid ( steroid part CNS disease treatment ) , case brain metastasis , stable improve image least 6 week completion definitive treatment . Any serious medical psychiatric illness would prevent either give informed consent receipt treatment . Patients pregnant nursing . Patients use tobacco nicotine product medication within last three month give significant effect erlotinib drug level . Diabetes . Defined HgbA1C ≥ 6.5 % . Prior metformin treatment OR EGFR target therapy . Rapidly progressive disease judge investigator ( Examples include rapidly deteriorate performance status symptomatic lymphangitic spread ) . Patient condition associate increase risk metforminassociated lactic acidosis ( e.g . congestive heart failure define New York Heart Association { NYHA } Class III IV functional status , history acidosis type ; habitual intake 3 alcoholic beverage per day ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Triple Negative</keyword>
	<keyword>Basal-like</keyword>
</DOC>